In plain language
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) designed to prompt the pituitary to release more growth hormone. Some versions add a chemical tag (DAC) that extends how long it stays active in the body. Human data is limited to early pharmacology work, so its long-term effects are not established.
What it is explored for
CJC-1295 is interesting because it works with the body rather than around it, nudging the pituitary to release its own growth hormone instead of replacing it. That gentler, GH-releasing angle, often paired with Ipamorelin, is why it draws so much interest in recovery and anti-aging conversations. Here is where interest and reported use are highest.
- Supporting the body's own growth-hormone release
- Recovery from exercise and physical stress
- Lean muscle and body composition
- Fat metabolism support
- Bone density support
- Deeper, more restful sleep
- Healthy aging and vitality
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
CJC-1295 mimics natural GHRH, the hypothalamic hormone that signals the pituitary gland to release growth hormone. The added DAC component is intended to bind albumin and slow clearance, lengthening its window of action.
- GHRH receptor activation. Binds pituitary GHRH receptors to stimulate pulsatile release of growth hormone.
- Extended half-life (DAC versions). The drug affinity complex binds plasma albumin, which in early studies sustained raised GH and IGF-1 levels for days.
- Downstream IGF-1. Increased growth hormone in turn raises circulating IGF-1, the mediator of many GH effects.
These mechanisms come mainly from a small early human pharmacology study and from manufacturer data. Long-term clinical outcomes in people are not established.
Evidence summary
Evidence for CJC-1295 is limited. An early-phase human study showed it can raise growth hormone and IGF-1 levels for an extended period, but there are no published, well-controlled trials measuring meaningful clinical outcomes such as body composition or strength. What it does to GH levels is clearer than whether that translates to benefit or safety.
Reported safety & side effects
Reported short-term effects in early studies include injection-site reactions, flushing, and headache. Because sustained GH and IGF-1 elevation carries theoretical risks and long-term human data is absent, its safety profile is not established.
Stacking notes
Full stacking guideA GHRH analog paired with a selective ghrelin-receptor peptide. They raise growth hormone through two different pathways, and ipamorelin is selective enough to avoid the large cortisol and prolactin spikes seen with older GHRPs.
IpamorelinMK-677 already raises growth hormone and IGF-1 strongly on its own. Adding another secretagogue compounds water retention, appetite, and insulin-resistance effects for little clear added benefit.
MK-677IpamorelinTwo peptides that both act as GHRH analogs are redundant. One occupies the same receptor the other would, so the combination adds cost and variables, not effect.
SermorelinGeneral educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is CJC-1295 FDA-approved?
No. CJC-1295 is not approved by the FDA for any use. It is sold as a research chemical and is not an approved medicine.
What is the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) version binds albumin in the blood and stays active far longer, producing prolonged GH and IGF-1 elevation. The version without DAC, often called Modified GRF 1-29, acts more briefly and mimics natural GH pulses more closely.
Is there human evidence it changes body composition?
Not in published controlled trials. Early studies measured hormone levels rather than outcomes like muscle or fat mass, so clinical benefit in people is not established.